Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in the US business during Q4 and FY26, alongside margin expansion and higher profitability. With investments in R&D, a pipeline of first-to-file opportunities and expansion across emerging markets, Lupin is building its presence in respiratory therapies, specialty medicines and higher-value pharmaceutical segments globally.